NovaBay Pharmaceuticals (NASDAQ:NBY) was downgraded by equities research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued to investors on Wednesday.
NASDAQ:NBY opened at $1.43 on Wednesday. NovaBay Pharmaceuticals has a 12 month low of $0.71 and a 12 month high of $3.85.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care.
Featured Story: Cost of Capital Explained
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.